USPTO Patent Application: TYK2 Inhibitor Dosage Forms
Summary
The USPTO has published a patent application (US20260083733A1) for novel dosage forms of a TYK2 inhibitor, BMS-986165, intended for treating autoimmune diseases. The application details stable and bioavailable formulations, including spray-dried dispersions in a solid polymer matrix.
What changed
This document is a USPTO patent application (US20260083733A1) for new dosage forms of a TYK2 inhibitor, identified as BMS-986165. The application, filed on December 2, 2025, describes formulations designed to be stable and bioavailable, specifically mentioning spray-dried dispersions within a solid polymer matrix. These formulations are intended for the treatment of autoimmune and auto-inflammatory diseases, including inflammatory bowel disease (IBD) and psoriasis.
As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signifies potential future intellectual property and market exclusivity for specific drug formulations. Pharmaceutical and drug manufacturers involved in the development of TYK2 inhibitors or treatments for autoimmune diseases should monitor this application and related patents for competitive intelligence and potential licensing opportunities.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DOSAGE FORMS FOR TYK2 INHIBITORS
Application US20260083733A1 Kind: A1 Mar 26, 2026
Inventors
Sherif Ibrahim Farag Badawy, Jonathan R. Brown, Candice Y. Choi, Christoph Gesenberg, Vivienne Gray, John Wynne Jones, Umesh Kestur, Balvinder S. Vig, Xiaotian S. Yin, Christopher A. Zordan, Corey Bloom, lan Yates
Abstract
Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis:
CPC Classifications
A61K 31/501 A61K 9/0053 A61K 9/2009 A61K 9/2013 A61K 9/2018 A61K 9/2054 A61K 9/284 A61K 45/06
Filing Date
2025-12-02
Application No.
19406921
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.